The research results update on Saikaike presented at the 22nd IMS Annual Meeting in 2025 by CARSGEN-B(02171).

CARSGEN-B (02171) announced that the long-term follow-up results of Zevor-cel (a autologous CAR-T cell product targeting BCMA, product number CT053) have been presented in a poster session at the 22nd International Myeloma Society Annual Meeting. The Phase I clinical trial update results of Zevor-cel were presented in a poster session titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" on the morning of September 17, 2025 in Toronto at the 22nd IMS annual meeting. Zevor-cel is a fully human anti-BCMA CAR-T cell product for the treatment of multiple myeloma (MM). The National Medical Products Administration approved the new drug application for Zevor-cel on February 23, 2024 for the treatment of relapsed or refractory multiple myeloma in adult patients who have progressed after at least 3 prior lines of therapy (including at least one proteasome inhibitor and immunomodulatory agent). Zevor-cel gained the designation of Regenerative Medicine Advanced Therapy (RMAT) and orphan drug status from the FDA in 2019.